Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China

被引:0
作者
Jian, Yuan [1 ]
Zhou, Huixing [1 ]
Xie, Weiwei [2 ]
Ren, Yuan [3 ]
Zhang, Zhiyao [1 ]
Yang, Guangzhong [1 ]
Geng, Chuanying [1 ]
Jia, Jing [1 ]
Chen, Wenming [1 ]
Huang, Wenrong [3 ]
Cen, Xinan [2 ]
Gao, Wen [1 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing, Peoples R China
[2] Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China
[3] Gen Hosp Peoples Liberat Army, Med Ctr 5, Dept Hematol, Beijing, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 04期
基金
北京市自然科学基金;
关键词
Multiple myeloma; renal impairment; dialysis dependence; dialysis independence; survival; DIAGNOSIS; RECOVERY; POPULATION; MORTALITY; FAILURE; OUTCOMES; THERAPY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Renal impairment (RI) is a very common complication of multiple myeloma (MM) with a negative impact on survival. Herein we retrospectively analyzed 334 MM patients with renal impairment at diagnosis from three hospi-tals in China. All 334 patients were divided into three groups, including dialysis dependence (n=43), dialysis inde-pendence (n=42), and without dialysis (n=249). Compared with dialysis independence and without dialysis groups, dialysis dependence group had the lowest overall hematologic response (48.8% vs. 97.6% vs. 77.1%, P<0.001) and overall renal response (0.0% vs. 97.6% vs. 72.7%, P<0.001), as well as the highest early mortality within 24 months (50.0% vs. 24.4% vs. 26.3%, P=0.006). Dialysis dependence group had similar progression-free survival (24 vs. 26 vs. 27 months, P=0.231) and significantly shorter overall survival (25 vs. 69 vs. 45 months, P=0.001). Dialysis dependence was independently associated with high mortality within 24 months and shorter overall survival. In conclusion, MM patients with dialysis dependence still tend to suffer a dismal disease course, including a high probability to suffer early mortality, worse hematological and renal response, as well as shorter survival. Dialysis independence could be very promising for survival improvement.
引用
收藏
页码:1571 / 1581
页数:11
相关论文
共 50 条
  • [21] Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China
    Liu, Junru
    Huang, He
    Li, Yan
    Liu, Lin
    Li, Jianyong
    Liu, Zhuogang
    Lu, Jin
    Ouyang, Jian
    Song, Yongping
    Zhou, Daobin
    Ren, Hanyun
    Ma, Jun
    Wang, Chun
    Yu, Li
    Zhou, Jin
    Wang, Jianmin
    Xiao, Yang
    Huang, Xiaojun
    Li, Juan
    TUMOR BIOLOGY, 2016, 37 (06) : 7893 - 7900
  • [22] Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
    Chen, Xuduan
    Luo, Xiaofeng
    Zu, Yanping
    Issa, Hajji Ally
    Li, Linlin
    Ye, Hong
    Yang, Ting
    Hu, Jianda
    Wei, Lixin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (09)
  • [23] Superior myeloma response with bortezomib-based regimen in multiple myeloma patients with renal impairment
    Bao, Li
    Lu, Jin
    Wang, Shihua
    Huang, Xiaojun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 6200 - 6209
  • [24] Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study
    de Vries, Joost C.
    Oortgiesen, Berdien
    Hemmelder, Marc H.
    van Roon, Eric
    Kibbelaar, Robby E.
    Veeger, Nic
    Hoogendoorn, Mels
    LEUKEMIA & LYMPHOMA, 2017, 58 (09) : 2101 - 2109
  • [25] Multiple Facets of Multiple Myeloma in Kidney Biopsy: A Multicenter Retrospective Study
    Shankar, Mythri
    Anandh, Urmila
    Guditi, Swarnalatha
    INDIAN JOURNAL OF NEPHROLOGY, 2024, 34 (01) : 31 - 36
  • [26] Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
    Klein, Ulrike
    Neben, Kai
    Hielscher, Thomas
    Heiss, Christiane
    Ho, Anthony D.
    Goldschmidt, Hartmut
    ANNALS OF HEMATOLOGY, 2011, 90 (04) : 429 - 439
  • [27] Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
    Morabito, Fortunato
    Gentile, Massimo
    Ciolli, Stefania
    Petrucci, Maria T.
    Galimberti, Sara
    Mele, Giuseppe
    Casulli, Antonio F.
    Mannina, Donato
    Piro, Eugenio
    Pinotti, Graziella
    Palmieri, Salvatore
    Catalano, Lucio
    Callea, Vincenzo
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Baldini, Luca
    Tosi, Patrizia
    Di Raimondo, Francesco
    Boccadoro, Mario
    Palumbo, Antonio
    Cavo, Michele
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (03) : 223 - 228
  • [28] Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
    Lalit Kumar
    Santosh Kumar Chellapuram
    Ramavat Dev
    Ankur Varshneya
    Satyajit Pawar
    Aparna Sharma
    Anjali Mookerjee
    Ranjit Kumar Sahoo
    Prabhat Singh Malik
    Atul Sharma
    Ritu Gupta
    Omdutta Sharma
    Ahitagni Biswas
    Rakesh Kumar
    Sanjay Thulkar
    Sauumyaranjan Mallick
    Clinical Hematology International, 2019, 1 (4) : 205 - 219
  • [29] Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report
    Wu, Tao
    Zhou, Jinmao
    Wang, Cunbang
    Wang, Binbin
    Zhang, Shuting
    Bai, Hai
    ONCOLOGY LETTERS, 2017, 14 (06) : 7318 - 7322
  • [30] Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution
    Andriandi
    Kamal, Achmad Fauzi
    ANNALS OF MEDICINE AND SURGERY, 2019, 41 : 11 - 15